CU23389B6 - Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica - Google Patents
Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémicaInfo
- Publication number
- CU23389B6 CU23389B6 CU20050284A CU20050284A CU23389B6 CU 23389 B6 CU23389 B6 CU 23389B6 CU 20050284 A CU20050284 A CU 20050284A CU 20050284 A CU20050284 A CU 20050284A CU 23389 B6 CU23389 B6 CU 23389B6
- Authority
- CU
- Cuba
- Prior art keywords
- inflammatory response
- pharmacological combination
- inflammatory
- citoprotector
- prevention
- Prior art date
Links
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 4
- 230000028709 inflammatory response Effects 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 230000001120 cytoprotective effect Effects 0.000 abstract 2
- 230000002757 inflammatory effect Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 101800003838 Epidermal growth factor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 101000779583 Limulus polyphemus Anti-lipopolysaccharide factor Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000002939 deleterious effect Effects 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 229940116977 epidermal growth factor Drugs 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000007124 immune defense Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 230000007246 mechanism Effects 0.000 abstract 1
- 230000003990 molecular pathway Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000004083 survival effect Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención trata de una combinación farmacológica entre una proteína con propiedades citoprotectoras y un péptido inmunomodulador. El Péptido de la combinación farmacológica es el LALF 31-52 lineal, que incrementa los mecanismos de defensa inmunológica, sin inducir una respuesta inflamatoria exacerbada. La proteína de la combinación farmacológica es el Factor de Crecimiento Epidérmico que posee un efecto citoprotector y activa la transducción de senales de genes de sobrevida celular. La combinación farmacológica de la presente invención confiere resistencia a las células sistémicas e inmunocomponentes, para tolerar el dano inducido por las citoquinas inflamatorias y por endotoxinas bacterianas, sin activar vías moleculares de apoptosis. Además, atenúa los eventos inflamatorios de la primera etapa de la sepsis y de la respuesta inflamatoria ante traumatismos estériles, permitiendo la defensa del organismo contra la invasión de patógenos o contra los mediadores de la inflamación, sin que la respuesta inflamatoria sea deletérea a su integridad.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050284A CU23389B6 (es) | 2005-12-29 | 2005-12-29 | Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica |
| BRPI0620817A BRPI0620817A2 (pt) | 2005-12-29 | 2006-12-28 | combinação farmacêutica para a prevenção e tratamento da síndrome de resposta inflamatória desencadeada por insultos sépticos ou estéreis |
| PCT/CU2006/000017 WO2007073703A1 (es) | 2005-12-29 | 2006-12-28 | Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica |
| ARP060105841A AR058875A1 (es) | 2005-12-29 | 2006-12-28 | Combinacion farmaceutica citoprotectora util en la prevencion y tratamiento del sindrome de respuesta inflamatoria sistemica |
| CA002635342A CA2635342A1 (en) | 2005-12-29 | 2006-12-28 | Cytoprotective pharmaceutical combination which can be used in the prevention and treatment of systemic inflammatory response syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20050284A CU23389B6 (es) | 2005-12-29 | 2005-12-29 | Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU23389B6 true CU23389B6 (es) | 2009-07-16 |
Family
ID=37773591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU20050284A CU23389B6 (es) | 2005-12-29 | 2005-12-29 | Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR058875A1 (es) |
| BR (1) | BRPI0620817A2 (es) |
| CA (1) | CA2635342A1 (es) |
| CU (1) | CU23389B6 (es) |
| WO (1) | WO2007073703A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5590004B2 (ja) * | 2011-10-24 | 2014-09-17 | 新日鐵住金株式会社 | 太陽光発電パネル用整流架台 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22700A1 (es) * | 1997-09-29 | 2001-07-31 | Ct Ingenieria Genetica Biotech | Formulación farmacéutica anti-viral que contiene un péptido de la proteína factor anti-lps de limulus y su uso |
| CU23157A1 (es) * | 2001-01-03 | 2006-07-18 | Ct Ingenieria Genetica Biotech | COMPOSICION FARMACéUTICA PARA EL TRATAMIENTO DEL DANO TISULAR DEBIDO A FALTA DE IRRIGACION SANGUINEA ARTERIAL |
-
2005
- 2005-12-29 CU CU20050284A patent/CU23389B6/es unknown
-
2006
- 2006-12-28 CA CA002635342A patent/CA2635342A1/en not_active Abandoned
- 2006-12-28 AR ARP060105841A patent/AR058875A1/es not_active Application Discontinuation
- 2006-12-28 WO PCT/CU2006/000017 patent/WO2007073703A1/es active Application Filing
- 2006-12-28 BR BRPI0620817A patent/BRPI0620817A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007073703A1 (es) | 2007-07-05 |
| CA2635342A1 (en) | 2007-07-05 |
| AR058875A1 (es) | 2008-02-27 |
| BRPI0620817A2 (pt) | 2016-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121658T1 (el) | Πεπτιδια και χρηση αυτων | |
| AR062281A1 (es) | Laminados en forma de lengueta elasticos y con forma | |
| GT201200125A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| BR112012032695A2 (pt) | cobertura plástica de célula dupla para aberturas arquitetônicas. | |
| GT201100006A (es) | Salicilatos acetilados con ácidos grasos y sus usos | |
| CO6290718A2 (es) | Patineta de dos bases con un sistema de amortiguacion con resortes | |
| WO2009051717A3 (en) | Human factor ix variants with an extended half life | |
| ATE485066T1 (de) | Medizinische ballons mit modifizierten oberflächen | |
| DE502008001664D1 (de) | Solarmodulanordnung und Dachanordnung | |
| WO2010144344A3 (en) | Melanocortin receptor-specific peptides | |
| EP2357190A3 (en) | Cyclic antimicrobial peptides | |
| CR10938A (es) | Efectos combinados del topiramato y el ondansetron sobre el consumo de alcohol | |
| ES2688030T3 (es) | Péptidos permeables celulares inhibidores de la ruta de transducción de la señal JNK para su uso en el tratamiento de enfermedades oculares inflamatorias | |
| HK1142828A1 (en) | Hydrolysable polymeric fmoc-linker | |
| BR0114093A (pt) | Pelìcula de poliolefina de camadas múltiplas como um substituto de uma pelìcula de pvc | |
| IL313142A (en) | Multi-stage adsorbent device and its uses for cooling and/or collecting atmospheric water | |
| CU23389B6 (es) | Combinación farmacéutica citoprotectora, útil en la prevención y tratamiento del síndrome de respuesta inflamatoria sistémica | |
| AR093647A1 (es) | Componente en microcapa para peliculas con barrera de gas/humedad mejorada por control de la orientacion laminar del cristal | |
| BR112017011280A2 (pt) | laminado de uma folha de material polimérico espesso e de uma folha de vidro fina | |
| CY1114125T1 (el) | Αδιπονεκτινη στην αγωγη εναντι πνευμονοπαθειας | |
| ITRM20040349A1 (it) | Peptidi antibatterici e loro analoghi. | |
| ES2528673B1 (es) | Péptido con actividad inhibidora de quorum sensing, polinucleótido que codifica dicho péptido y sus aplicaciones | |
| WO2009068682A3 (en) | Phenyl-oxetanyl-derivatives | |
| EP2327393A3 (de) | Verwendung von Zingeron gegen Altershaut | |
| WO2010020677A3 (en) | Protein c variants |